- Home
- AAON vs JAZZ Comparison
AAON vs JAZZ Comparison
Compare AAON & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAON
- JAZZ
- Stock Information
- Founded
- AAON 1988
- JAZZ 2003
- Country
- AAON United States
- JAZZ Ireland
- Employees
- AAON N/A
- JAZZ N/A
- Industry
- AAON Industrial Machinery/Components
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- AAON Industrials
- JAZZ Health Care
- Exchange
- AAON Nasdaq
- JAZZ Nasdaq
- Market Cap
- AAON 9.2B
- JAZZ 8.4B
- IPO Year
- AAON N/A
- JAZZ 2007
- Fundamental
- Price
- AAON $78.08
- JAZZ $122.92
- Analyst Decision
- AAON Buy
- JAZZ Strong Buy
- Analyst Count
- AAON 5
- JAZZ 13
- Target Price
- AAON $115.50
- JAZZ $187.15
- AVG Volume (30 Days)
- AAON 1.2M
- JAZZ 1.3M
- Earning Date
- AAON 05-01-2025
- JAZZ 04-30-2025
- Dividend Yield
- AAON 0.51%
- JAZZ N/A
- EPS Growth
- AAON N/A
- JAZZ 41.75
- EPS
- AAON 2.02
- JAZZ 8.65
- Revenue
- AAON $1,200,635,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- AAON $23.52
- JAZZ $7.30
- Revenue Next Year
- AAON $13.01
- JAZZ $4.01
- P/E Ratio
- AAON $38.65
- JAZZ $14.21
- Revenue Growth
- AAON 2.75
- JAZZ 6.12
- 52 Week Low
- AAON $69.52
- JAZZ $99.06
- 52 Week High
- AAON $144.07
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- AAON 36.23
- JAZZ 32.69
- Support Level
- AAON $77.29
- JAZZ $137.74
- Resistance Level
- AAON $85.12
- JAZZ $142.64
- Average True Range (ATR)
- AAON 3.30
- JAZZ 3.87
- MACD
- AAON 1.21
- JAZZ -2.12
- Stochastic Oscillator
- AAON 10.42
- JAZZ 0.45
About AAON AAON Inc.
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. AAON's products serve the commercial and industrial new construction and replacement markets, primarily in North America.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.